Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 8/20 | 0.54 |
| ▸ | F2 | P00734 | 3/20 | 0.54 |
| ▸ | CTSG | P08311 | 2/20 | 0.54 |
| ▸ | PREP | P48147 | 3/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31460272 | 0.88 | ELANE (0.54) | ELANEF2CTSGPREPKLK7 | |
| SCHEMBL1875019 | 0.87 | PREP (0.54) | PREPKLK7KLK5ACE2HSD17B10 | |
| SCHEMBL30745190 | 0.82 | PREP (0.52) | PREPKLK7KLK5ACE2HSD17B10 | |
| SCHEMBL25759230 | 0.82 | PREP (0.52) | PREPKLK7KLK5ACE2HSD17B10 | |
| SCHEMBL25286331 | 0.82 | PREP (0.52) | PREPKLK7KLK5ACE2HSD17B10 | |
| SCHEMBL24667753 | 0.82 | PREP (0.54) | ELANEF2CTSGPREPACE2 | |
| SCHEMBL28826460 | 0.82 | PREP (0.54) | ELANEF2CTSGPREPACE2 | |
| SCHEMBL10310516 | 0.81 | PREP (0.49) | PREPKLK7KLK5ACE2HSD17B10 | |
| SCHEMBL27766855 | 0.81 | PREP (0.56) | PREPKLK7KLK5ACE2HSD17B10 | |
| SCHEMBL30745850 | 0.80 | TMEM97 (0.48) | PREPKLK7KLK5ACE2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192614-A1 | METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE | CHENGDA PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192614-A1 | METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE | TALDO1, RPL22, RPS20 | ELANE 994/4885F2 1083/4885CTSG 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.